Delirezh Nowruz, Moazzeni Seyed Mohammad, Shokri Fazel, Shokrgozar Mohammad Ali, Atri Morteza, Kokhaei Parviz
Department of Cellular and Molecular Biotechnology, Institute of Biotechnology, Urmia University, Urmia, Iran.
Cell Immunol. 2009;257(1-2):23-31. doi: 10.1016/j.cellimm.2009.02.002.
Dendritic cell (DCs) based immunotherapy has received increased interest in the treatment of specific malignancies including breast cancer. In this in vitro study, T cell responses, which are induced by monocyte-derived DCs pulsed with apoptotic breast tumor cells (ApTC), were analyzed in terms of proliferation, specific cytotoxicity, and cytokine release. Nylon wool-enriched T lymphocytes from five patients with breast cancer stimulated with monocyte-derived DCs pulsed with apoptotic tumor cells in vitro and their proliferation response were analyzed by [(3)H] thymidine uptake and specific cytotoxic activity of tumor antigen-primed T cells after three rounds of weekly stimulation by flow cytometry. Interferon-gamma (IFN-gamma) and interleukin-4 (IL-4) cytokine release assay was carried out 24h after the last stimulation. The supernatant from primed T cells was collected and analyzed using commercially available ELISA kits. T cell proliferation assays revealed that DCs pulsed with apoptotic tumor cell could stimulate an autologous T cell proliferation response with stimulation indices of 5-21. The T cell-mediated cytotoxicity assay demonstrated that tumor antigen-primed T cells could kill significantly more autologous tumor cells than normal cells (P<0.05). These cells had variable amounts of cytotoxic activity against K562 cells. Primed T cells released both IFN-gamma and IL-4 in response to re-stimulation by antigen-pulsed DCs, but were dominated by IFN-gamma production in two out of five patients and IL-4 production in three out of five patients. In conclusion, our results suggested that DCs pulsed with apoptotic breast tumor cells could elicit effective specific antitumor T cell responses in vitro. Therefore, vaccination with DCs pulsed with apoptotic tumor cells may be considered as a novel strategy for immunotherapy of patients with breast cancer refractory to standard modalities.
基于树突状细胞(DCs)的免疫疗法在包括乳腺癌在内的特定恶性肿瘤治疗中受到了越来越多的关注。在这项体外研究中,分析了由凋亡乳腺肿瘤细胞(ApTC)脉冲处理的单核细胞衍生DCs诱导的T细胞反应,包括增殖、特异性细胞毒性和细胞因子释放。从五名乳腺癌患者中通过尼龙毛富集T淋巴细胞,使其在体外与经凋亡肿瘤细胞脉冲处理的单核细胞衍生DCs刺激,通过[³H]胸苷摄取分析其增殖反应,并在每周三轮刺激后通过流式细胞术分析肿瘤抗原致敏T细胞的特异性细胞毒性活性。在最后一次刺激后24小时进行干扰素-γ(IFN-γ)和白细胞介素-4(IL-4)细胞因子释放测定。收集致敏T细胞的上清液并使用市售ELISA试剂盒进行分析。T细胞增殖测定显示,经凋亡肿瘤细胞脉冲处理的DCs可刺激自体T细胞增殖反应,刺激指数为5-21。T细胞介导的细胞毒性测定表明,肿瘤抗原致敏T细胞对自体肿瘤细胞的杀伤作用明显高于正常细胞(P<0.05)。这些细胞对K562细胞具有不同程度的细胞毒性活性。致敏T细胞在抗原脉冲DCs再次刺激下释放IFN-γ和IL-4,但在五名患者中有两名以IFN-γ产生为主,在五名患者中有三名以IL-4产生为主。总之,我们的结果表明,经凋亡乳腺肿瘤细胞脉冲处理的DCs可在体外引发有效的特异性抗肿瘤T细胞反应。因此,用经凋亡肿瘤细胞脉冲处理的DCs进行疫苗接种可被视为对标准治疗方式难治的乳腺癌患者进行免疫治疗的一种新策略。